Literature DB >> 18721505

Usefulness of paradoxical systolic blood pressure increase after exercise as a predictor of cardiovascular mortality.

Chi-Lun Huang1, Ta-Chen Su, Wen-Jone Chen, Lian-Yu Lin, Wen-Lin Wang, Mee-Huei Feng, Chiau-Suong Liau, Yuan-Teh Lee, Ming-Fong Chen.   

Abstract

Exercise treadmill testing (ETT) is a well-accepted examination for patients with suspected coronary artery disease (CAD), and exercise induced ST-segment deviation is commonly used for CAD detection. However, recent evidence shows that systolic blood pressure (SBP) changes during and after exercise were associated with CAD severity, risk of acute myocardial infarction and stroke, new-onset hypertension, and even cardiovascular mortality. We retrospectively assessed 3,054 patients referred for ETT in 1996. Blood pressure and heart rate were recorded at rest, during peak exercise, and 1 and 3 min after exercise. SBP at 3 min of recovery equal to or higher than that at 1-min of recovery was defined as paradoxical SBP increase. These patients were categorized into 4 groups according to ETT ST-segment change and postexercise SBP change. After 10 years of follow-up, 346 patients (11%) died, with 129 (4%) dying from cardiovascular disease (CVD). Among the 4 groups, patients with ischemic ST-segment change and paradoxical SBP increase were associated with a higher risk for mortality, with odds ratios of 1.86 (95% confidence interval 1.31 to 2.65) for all-cause mortality and 3.18 (95% confidence interval 1.94 to 5.20) for CVD mortality, respectively. Patients with isolated paradoxical SBP increase still had a higher risk of CVD mortality (odds ratio 1.80, 95% confidence interval 1.70 to 3.04), even after controlling other cardiovascular risk factors. In subgroup analysis of 346 mortality subjects, patients with ischemic ST-segment change and paradoxical SBP increase would be more likely to die from CVD. In conclusion, compared with ischemic ST-segment change, paradoxical SBP increase after exercise is an important and significant predictor of CVD mortality.

Entities:  

Mesh:

Year:  2008        PMID: 18721505     DOI: 10.1016/j.amjcard.2008.04.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Impact of Stimulant Medication Use on Heart Rate and Systolic Blood Pressure During Submaximal Exercise Treadmill Testing in Adolescents.

Authors:  Arthur N Westover; Paul A Nakonezny; Bryon Adinoff; Edson Sherwood Brown; Ethan A Halm
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-09-14       Impact factor: 2.576

2.  The circadian system modulates the rate of recovery of systolic blood pressure after exercise in humans.

Authors:  Jingyi Qian; Frank Ajl Scheer; Kun Hu; Steven A Shea
Journal:  Sleep       Date:  2020-04-15       Impact factor: 5.849

Review 3.  Exercise blood pressure: clinical relevance and correct measurement.

Authors:  J E Sharman; A LaGerche
Journal:  J Hum Hypertens       Date:  2014-10-02       Impact factor: 3.012

4.  Heart Rate Recovery and Systolic Blood Pressure Recovery After Maximal Exercise in Prevalent Users of Stimulant Medications.

Authors:  Arthur N Westover; Paul A Nakonezny; Carolyn E Barlow; Bryon Adinoff; E Sherwood Brown; Ethan A Halm; Wanpen Vongpatanasin; Laura F DeFina
Journal:  J Clin Psychopharmacol       Date:  2016-06       Impact factor: 3.153

5.  The interplay of exercise heart rate and blood pressure as a predictor of coronary artery disease and arterial hypertension.

Authors:  Andreas P Michaelides; Charalampos I Liakos; Gregory P Vyssoulis; Evangelos I Chatzistamatiou; Maria I Markou; Vanessa Tzamou; Christodoulos I Stefanadis
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-11-26       Impact factor: 3.738

6.  Incremental Diagnostic Performance of Combined Parameters in the Detection of Severe Coronary Artery Disease Using Exercise Gated Myocardial Perfusion Imaging.

Authors:  Chia-Ju Liu; Yen-Wen Wu; Kuan-Yin Ko; Yi-Chieh Chen; Mei-Fang Cheng; Ruoh-Fang Yen; Kai-Yuan Tzen
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.